Sino Biopharmaceutical : VOLUNTARY ANNOUNCEMENT

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT

"ADEMETIONINE 1,4-BUTANEDISULFONATE FOR INJECTION"

OBTAINS APPROVAL FOR DRUG REGISTRATION

The board of directors (the "Board") of Sino Biopharmaceutical Limited (the "Company", together with its subsidiaries, the "Group") announces that the "Ademetionine 1,4-Butanedisulfonate for Injection" (brand name "Baixinuo" ( 百西諾)), a cholagogue developed by Chia-Tai Tianqing Pharmaceutical Group Co., Ltd, a subsidiary of the Company, has obtained the approval for drug registration granted by the National Medical Products Administration of the People's Republic of China. This product is applicable to the prevention of intrahepatic cholestasis before and during cirrhosis and intrahepatic cholestasis during pregnancy.

Ademetionine is a physiologically active molecule present in human body, serving as a methyl donor and precursor of physiological sulfur compounds in various important biochemical reactions, which are conducive to the prevention of intrahepatic cholestasis. Besides, ademetionine shows superb efficacy on liver damage caused by viral hepatitis and alcohol, including cirrhosis. The drug is clinically safe and can be used by pregnant women.

The approval for drug registration obtained by the Ademetionine 1,4-Butanedisulfonate for Injection developed by the Group will further enrich the Group's product lines and strengthen its leading position in the field of liver health in China.

By order of the Board

Sino Biopharmaceutical Limited

Tse, Theresa Y Y

Chairwoman

Hong Kong, 10 December 2019

1

As at the date of this announcement, the Board comprises eight Executive Directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and four Independent Non-Executive Directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong and Mr. Zhang Lu Fu.

2